ProMIS Neurosciences Inc. (PMN) ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ProMIS Neurosciences, Inc. NASDAQ:PMN Healthcare · Biotechnology
Mkt Cap $27.89M
EV -
SI 4.1%
Net Cash/Sh -
Prev close $3.31 -5.74%Open $3.12 -0.64%Now $3.10 VOL 94K $ Vol $303K RVOL 0.23x
Mkt Cap $27.89M
EV -
VOL 94K sh
$ Vol $303K
RVOL 0.23×
SI 4.1%
Net Cash/Sh -
Press Release
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
ProMIS Neurosciences licensed TXP1, a transferrin receptor 1 (TfR1)-targeting brain-selective shuttling technology, from Ossianix for use with its lead Alzheimer's antibody PMN310. In Ossianix preclinical studies, including non-human primate work, TXP1 increased antibody delivery to the brain by more than 65-fold with no off-target accumulation in major organs reported. ProMIS holds options to extend TXP1 to PMN442 (alpha-synuclein/Parkinson's) and PMN267 (TDP-43/ALS), and says the deal does not change its disclosed cash runway through 2027.
• 12h ago AI analysis › Press Release
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
ProMIS Neurosciences reported a Q3 2026 net loss of $8.2 million, or $(0.89) per share, with cash of $44.1 million as of September 30, 2026. The company reaffirmed that PRECISE-AD Phase 1b topline data for PMN310 remains on track for Q1 2027, and said cash funds operations through 2027 — beyond the readout. Interim data showed no ARIA-E and encouraging biomarker signals.
• 4d ago AI analysis › Press Release
ProMIS Neurosciences to Participate in Upcoming Conferences in November
ProMIS Neurosciences announced participation in six November 2026 investor and scientific conferences, with CEO Neil Warma delivering presentations and fireside chats. Venues include the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, CTAD, and the Evercore Healthcare Conference.
• 12d ago AI analysis › Press Release
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
ProMIS Neurosciences will report third quarter 2026 financial results and provide a business update on November 12, 2026. A conference call and webcast are scheduled the same day at 4:30 p.m. ET, with a replay to follow in the investors section of the company website.
• 14d ago AI analysis › Press Release
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Rubino spent more than 15 years at Biogen and Roche, most recently as VP and Global Head of Alzheimer's Disease & Multiple Sclerosis Medical at Biogen, supporting the LEQEMBI franchise across 52 market approvals. She will lead commercial and launch-readiness strategy for PMN310 ahead of unblinded 12-month PRECISE-AD topline data expected in Q1 2027.
• 1mo ago AI analysis › Press Release
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
ProMIS Neurosciences announced its participation in several investor conferences throughout September 2026, including events hosted by Cantor, Moody Capital, and H.C. Wainwright. Management, including CEO Neil Warma and CMO Dr. Larry Altstiel, will discuss the EpiSelect platform and the PMN310 candidate currently in the PRECISE-AD Phase 1b trial.
• 2mo ago AI analysis › Press Release
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS reported Q2 2026 financial results with a net loss of $11.7 million ($1.28 per share), highlighting a strengthened balance sheet with $53.4 million in cash following a January private placement. The company announced positive blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, showing zero cases of ARIA-E and favorable trends in key biomarkers plasma pTau217 and CSF MTBR-tau243.
• 3mo ago AI analysis › Press Release
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
ProMIS Neurosciences announced it will report its second quarter 2026 financial results and provide a corporate business update on August 13, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
• 3mo ago AI analysis › Press Release
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
ProMIS Neurosciences reported positive blinded interim data from the Phase 1b PRECISE-AD trial of PMN310 for Alzheimer’s disease, showing no cases of ARIA-E across all genotypes in 136 patients. The safety profile was favorable with only 4.4% mild ARIA-H, even among high-risk APOE4 homozygotes, and there were no treatment-related discontinuations. Biomarker data indicated early target engagement, with 68.5% of patients showing a decline in plasma pTau217 and 62.5% showing a decline in CSF MTBR-tau243. These blinded trends align with the trial's 3:1 active-to-placebo ratio but are not yet determinative of efficacy.
• 3mo ago AI analysis › Press Release
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences announced a webinar scheduled for July 28, 2026, featuring KOLs Dr. Will Mantyh and Dr. Michael Weiner to discuss six-month blinded interim data from the PRECISE-AD Phase 1b trial of PMN310 in Alzheimer's disease. The randomized, double-blind, placebo-controlled study has completed enrollment of 144 participants across three dosing cohorts, with the upcoming analysis focused on blinded aggregate safety data and biomarker trends.
• 3mo ago AI analysis › Press Release ● Major
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences reported positive Phase 1a data for its Alzheimer's candidate PMN310, demonstrating the first human evidence of dose-dependent target engagement of amyloid-beta oligomers. Analysis using the sFIDA assay developed with partner attyloid showed a reduction in oligomers in cerebrospinal fluid, a half-life of approximately 27 days, and high selectivity with no plaque binding.
• 4mo ago AI analysis › Press Release
ProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences will participate in several major healthcare conferences in June 2026, including presentations at the Jefferies Global Healthcare Conference and Wolfe Research’s Virtual Alzheimer’s R&D Day. CEO Neil Warma will discuss the company’s EpiSelect platform and lead Alzheimer’s candidate PMN310, which targets toxic amyloid-beta oligomers.
• 5mo ago AI analysis › Press Release ● Major
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
globenewswire.com • 6mo ago